Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jaad.2025.02.089 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Discount pharmacies may save patients significant money on androgenetic alopecia medications compared to both traditional pharmacies and direct-to-consumer companies.
J Am Acad Dermatol
March 2025
Department of Dermatology, Lewis Katz School of Medicine, Temple University, Philadelphia, PA. Electronic address:
Long-term cost-effectiveness of health behaviour intervention to manage type 2 diabetes in Nepal.
BMC Med
March 2025
Health Economics and Policy Evaluation Research (HEPER) Group, Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, Australia.
Background: Long-term cost-effectiveness analyses of health behaviour interventions to effectively manage type 2 diabetes mellitus (T2DM) in low-income countries are crucial for minimising economic burden and optimising resource allocation. Therefore, this study aimed to estimate the long-term cost-effectiveness of implementing a health behaviour intervention to manage T2DM in Nepal.
Methods: A Markov model in combination with a decision tree was developed to compare the costs and outcomes of the health behaviour intervention against usual care among 481 (238-intervention and 243-control) participants from healthcare system and societal perspectives.
Cost-utility analysis of add-on Qili Qiangxin capsules in chronic heart failure with reduced ejection fraction in China.
ESC Heart Fail
March 2025
Department of Pharmacy, Yantai Yuhuangding Hospital, Yantai, Shandong, China.
Aims: The study aimed to analyse the cost-utility of Chinese patent medicine Qili Qiangxin (QLQX) capsules in heart failure with a reduced ejection fraction from the healthcare payer's perspective.
Methods And Results: From the perspective of the healthcare payer, a Markov model was established to estimate the cost-utility of adding QLQX capsules to standard treatment versus standard treatment. A 19-year lifetime horizon was chosen with a 3-month cycle in the base case analysis.
Estimation of the Effects and Costs of Lifestyle Intervention and Treatment With Voglibose in the Japanese Prediabetic Population: A Cost-Effectiveness Analysis.
Value Health Reg Issues
March 2025
Faculty of Medicine, Department of Medical Informatics and Statistics, Niigata University, Niigata, Japan.
Objectives: Prediabetes is a condition in which blood glucose levels are higher than normal but not high enough for a type 2 diabetes (T2DM) diagnosis. Lifestyle and pharmacological interventions, such as voglibose, an alpha-glucosidase inhibitor that reduces postprandial hyperglycemia, can address pathophysiological deficits in prediabetes. In Japan, voglibose is approved for preventing T2DM in patients with impaired glucose tolerance.
View Article and Find Full Text PDFCurrent and Future Cost Burden of Myocardial Infarction in Australia: Dynamic Multistate Markov Model.
J Gen Intern Med
March 2025
Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, Australia.
Introduction: Myocardial infarction (MI) imposes a significant health burden to the Australian population. However, detailed economic implication of MI on the Australian healthcare system has not been exhaustively explored.
Objective: To estimate the current chronic management cost and project the future healthcare cost burden of MI, from the Australian healthcare system perspective.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!